burgeon
发表于 2025-3-21 16:07:41
书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0666805<br><br> <br><br>书目名称Nolph and Gokal‘s Textbook of Peritoneal Dialysis读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0666805<br><br> <br><br>
助记
发表于 2025-3-21 21:27:25
Urgent-Start Peritoneal Dialysis,ns and serious infections appear to be better in urgent-start PD than urgent HD with a CVC. In this chapter, we will define urgent-start PD, highlight key steps in creating an urgent-start PD program, review established clinical pathways, and discuss outcomes in urgent-start PD.
休闲
发表于 2025-3-22 00:35:03
New Peritoneal Dialysis Solutions and Solutions on the Horizon,the long exchange provides sustained ultrafiltration and provides more ultrafiltration than 3.86%/4.25% glucose dialysate. However, its use is limited to one daily exchange to prevent excessive maltose accumulation. Combinations with low molecular osmotic agents are interesting, but not commercially
FILTH
发表于 2025-3-22 04:52:37
Blood Pressure Control in Peritoneal Dialysis, appropriate antihypertensive agent should be individualized and should take into consideration the presence of comorbidities and other clinical characteristics of each patient. β-Blockers are our preferred antihypertensive drug class in pharmacotherapy of hypertension in patients on dialysis. Long-
独白
发表于 2025-3-22 11:09:38
Peritoneal Infections in Peritoneal Dialysis (PD Peritonitis),on institutional anti-biogram. Emerging drug resistance poses challenges as there is a paucity of pharmacokinetic and -dynamic data on newer antimicrobials. PD catheter removal is necessary for difficult to treat pathogens, tunnel infection, and refractory, recurrent, or serious infections. Preventi
genuine
发表于 2025-3-22 14:46:35
http://reply.papertrans.cn/67/6669/666805/666805_6.png
Capture
发表于 2025-3-22 17:48:39
Calcium, Phosphate, and Renal Osteodystrophy,ctrum of disorders associated with this metabolic state..This chapter attempts to outline the manifestations of mineral and bone disorder in the context of CKD with a focus on PD dependent end-stage kidney disease including the recent advances and consensus guidance on its management.
amorphous
发表于 2025-3-23 00:44:44
http://reply.papertrans.cn/67/6669/666805/666805_8.png
教育学
发表于 2025-3-23 03:47:22
Vascular Calcification and Calciphylaxis in Peritoneal Dialysis Patients,nary artery disease in patients with and without CKD. Medial calcium deposition disproportionately affects patients with CKD and results in arterial stiffness and ventricular dysfunction. A third form of ectopic calcification: Calciphylaxis, will also be reviewed here. In Calciphylaxis there is medi
hypertension
发表于 2025-3-23 09:31:53
Claire Kennedy,Joanne M. Bargmanon is available at most research institu tions. Therefore light absorption and paramagnetic resonance are treated in depth. The principles described in the lat978-3-642-81150-0978-3-642-81148-7Series ISSN 0077-0221